Guest: Rosalyn Adigun, M.D., Pharm.D.
Host: S. Allen Luis, M.B.B.S., Ph.D.
In this episode of Mayo Clinic’s “Interviews With the Experts,” Dr. Allen Luis interviews Dr. Rosalyn Adigun on transthyretin cardiac amyloidosis. Listeners will come away with an in depth overview of the evolution of therapy choices for affected person recognized with transthyretin amyloid cardiomyopathy, highlighting historic views, early registration research, present therapy choices, and an outlook on future instructions within the administration of transthyretin cardiac amyloidosis.
Topics Discussed:
• Overview of the historic views on the analysis and administration of transthyretin amyloidosis.
• Current therapy choices obtainable for transthyretin amyloid cardiomyopathy, and components that ought to information a clinician’s resolution relating to the selection of remedy.
• Treatment choices within the coming years.
• Ongoing analysis initiatives within the administration of cardiac amyloidosis.
0:00 Introduction and welcome with Dr. Allen Luis
2:00 Clinical focus and diagnostic emphasis
3:51 Recognizing early associations and purple flags
5:49 Role of NT-proBNP in illness analysis
8:05 Pathway after monoclonal protein detection
10:19 Addressing equivocal scintigraphy outcomes
12:20 Summary and medical interpretation factors
14:17 Managing cardiac amyloidosis shows
16:40 Identifying diagnostic pitfalls and limitations
18:43 Gene-silencing therapies and rising choices
20:43 Case-based insights and therapy outcomes
From Mayo Clinic to your inbox, sign-up at no cost: https://mayocl.in/3e71zfi
Visit Mayo Clinic: https://mayocl.in/2COVmlm
Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/
Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/
Follow Mayo Clinic on X, previously Twitter: https://x.com/MayoClinic
Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic
